Abstract

Kerkeni M, Saïdi A, Bouzidi H, Letaief A and Hammami M

Advanced glycation end products (AGEs) and their receptors are prominent contributors to diabetic renal disease and clinical importance of AGEs toxicity had been rarely reported. We measured serum AGE, sRAGE and pentosidine levels in diabetic patients with and without nephropathy and examined whether these biomarkers are related to renal function impairment. We included 30 healthy control subjects and 100 diabetic patients who were further divided into 2 subgroups: one with 30 patients who had normal eGFR, the other with 70 patients who had reduced eGFR. AGEs, sRAGE and pentosidine were measured in serum by ELISA. Serum levels of AGEs, sRAGE and pentosidine were significantly increased in diabetic patients compared to controls (579.78 ± 113.28 vs. 508.83 ± 119.68 pg/ml; 169.17 ± 30.41 vs. 148.72 ± 32.73 pg/ml; 247.84 ± 21.42 vs. 214.03 ± 55.05 pg/ml, P < 0.001, P < 0.01, P < 0.05 respectively). Diabetic patients with chronic kidney disease (CKD) showed an increased level of AGEs, sRAGE and pentosidine compared to diabetic patients without CKD (P < 0.01, P < 0.05, P < 0.05 respectively). In diabetic patients who had reduced eGFR, serum AGEs, sRAGE and pentosidine levels were significantly higher in patients with eGFR< 60, than in those with 60